Anirban Basu, PhD
Articles
March 27th 2017
Impact of a Value-Based Formulary in Three Chronic Disease Cohorts
Kai Yeung, PharmD, PhD Anirban Basu, PhD Zachary A. Marcum, PharmD, PhD John B. Watkins, PharmD, MPH, BCPS Sean D. Sullivan, PhD
A value-based formulary was implemented that used cost-effectiveness analysis to inform medication co-payments. Diabetes cohort expenditures decreased by $9 per member per month.
Latest Updated Articles
Published: November 15th 2024 | Updated: November 19th 2024
FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation
Published: April 1st 2024 | Updated: November 5th 2024
What We're Reading: Concierge Nonprofit Hospitals; Kaiser Permanente Elderly Care Program; Health Care Not Among Top Voter Issues
Published: October 21st 2024 | Updated: October 24th 2024
Lower Diagnostic Error Rates Found Among Hospitalized Patients During Care Transitions
Published: September 26th 2024 | Updated: October 1st 2024
Addressing Natural Disaster Takes Cooperation, Preparation to Ensure Patient Health
Published: May 9th 2024 | Updated: May 21st 2024
FDA Accepts Nivolumab Subcutaneous Injection Application, With Potential to Boost Access to PD-1 Inhibitors
Published: November 1st 2024 | Updated: November 21st 2024
Table Multiple Myeloma Trials November 2024
